中国生物制药减重“贴片”新药在美国获批临床;益方生物重启港股上市申请|医药早参

每日经济新闻
7 hours ago

丨 2026年8月25日星期二丨  NO.1中国生物制药GLP-1减重“贴片”新药在美国获批临床  中国生物制药宣布CPX301可溶微针获美国FDA临床试验默示许可,拟用于体重管理。CPX301是中国生物制药核心企业北京泰德制药研发的GLP-1受体激动剂可溶微针贴片,具有给药便捷、递送高效、无菌安全、储运便利的特点,有望为需要长期体重管理的人群提供一种新的给药选择。  点评:该GLP-1微针减重...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10